This highlights the efficacy of T cell therapy to influence PD-1 expression without additional intervention, such as anti-PD-1 blocking antibodies, like e.g. Nivolumab which are approved by the U.S. Food and Drug Administration and are currently used for HCC treatment (64). Here, PDCD1 is linked to hepatocellular carcinoma.